A Phase Ib/II Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin Lymphoma

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

117

Participants

Timeline

Start Date

March 8, 2019

Primary Completion Date

October 12, 2023

Study Completion Date

October 12, 2023

Conditions
B-cell Non-Hodgkin Lymphoma
Interventions
DRUG

Mosunetuzumab

Participants will receive intravenous (IV) mosunetuzumab.

DRUG

Polatuzumab Vedotin

Participants will receive polatuzumab vedotin via IV.

DRUG

Rituxumab

Participants will receive rituxumab via IV.

DRUG

Cyclophosphamide

Participants will receive cyclophosphamide via IV.

DRUG

Doxorubicin

Participants will receive doxorubicin via IV.

DRUG

Vincristine

Participants will receive vincristine via IV.

DRUG

Prednisone

Participants will receive oral prednisone.

DRUG

Tocilizumab

Participants will receive tocilizumab via IV.

Trial Locations (41)

1090

Medizinische Universität Wien, Allgemeines Krankenhaus der Stadt Wien, Vienna

1140

Hanusch-Krankenhaus, Vienna

4400

LKH Steyr, Steyr

5020

Uniklinikum Salzburg, LKH; Univ.Klinik f. Innere Medizin III der PMU, Salzburg

8041

Hospital de la Santa Creu i Sant Pau, Barcelona

10003

Hospital San Pedro de Alcantara; Servicio de Hematología, Cáceres

20007

Georgetown University Medical Center, Washington D.C.

28007

Hospital General Universitario Gregorio Marañon, Madrid

28041

Hospital Universitario 12 de Octubre, Madrid

28046

Hospital Universitario La Paz, Madrid

31008

Clinica Universidad de Navarra, Pamplona

33136

University of Miami Miller School of Medicine, Miami

35233

University of Alabama Birmingham, Birmingham

37232

Vanderbilt University Medical Center, Nashville

41071

Hospital Universitario Virgen Macarena, Seville

44805

Centre Henri Becquerel- Centre de Lutte Contre le Cancer, Saint-Herblain

48109

University of Michigan, Ann Arbor

50612

Pusan National University Yangsan Hospital, Gyeongsangnam-do

55905

Mayo Clinic Cancer Center, Rochester

66205

University of Kansas Cancer Center, Westwood

69008

Centre Leon Berard, Lyon

75475

Hôpital Saint-Louis, Paris

76508

Scott and White Hospital; Cancer Center, Temple

85234

Banner MD Anderson Cancer Center, Gilbert

92093

University of California; Moores Cancer Center, La Jolla

94010

CHU Henri Mondor; Service d'Oncologie Medicale, Créteil

94805

Gustave Roussy, Villejuif

90404-2023

University of California, Los Angeles (UCLA) - Hematology/Oncology Santa Monica, Santa Monica

02215

Dana-Farber Cancer Institute, Boston

02903-4923

Rhode Island Hospital, Providence

77030-4009

The University of Texas MD Anderson Cancer Center, Houston

53226-3596

Medical College of Wisconsin, Inc., Milwaukee

44-102

Maria Sklodowska-Curie Memorial Cancer Centre, Gliwice

30-501

Ma?opolskie Centrum Medyczne, Krakow

76-200

Wojewodzki Szpital Specjalistyczny im. Janusza Korczaka, Słupsk

02-776

Instytut Hematologii i Transfuzjologii; Klinika Zaburze? Hemostazy i Chorób Wewn?trznych, Warsaw

Unknown

Katedra i Klinika Hematologii; Nowotworów Krwi i Transplantacji Szpiku, Wroc?aw

03080

Seoul National University Hospital, Seoul

05505

Asan Medical Center, Seoul

06351

Samsung Medical Center, Seoul

08916

Institut Catala d?Oncologia Hospital Germans Trias i Pujol, Badalona

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT03677141 - A Phase Ib/II Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin Lymphoma | Biotech Hunter | Biotech Hunter